The influence of growth hormone on pediatric body composition: A systematic review.
body composition
fat mass
growth hormone
growth hormone deficiency
lean body mass
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
09
11
2022
accepted:
30
01
2023
entrez:
27
2
2023
pubmed:
28
2
2023
medline:
3
3
2023
Statut:
epublish
Résumé
Growth hormone (GH) affects metabolism and regulates growth in childhood. The most prominent feature of GH deficiency (GHD) in children is diminished height velocity that eventually leads to short stature. In adult-onset GHD, lean body mass (LBM) is reduced, and visceral fat mass (FM) increased. Beneficial effects of GH treatment on body composition in adults with GHD, including an increase in muscle mass and a decrease in FM, are well established. Relatively few studies have investigated the effects of GH treatment on the body composition of pediatric patients with idiopathic or hypothalamic-pituitary disease-associated GH deficiency. This systematic review aimed to summarize available evidence relating to the effects of GH treatment on body composition in children with GHD. The PubMed, Science Direct, Cochrane Trials, and Embase databases, were searched with keywords including "GH", "body composition", "children", and "growth hormone" for English-language articles, published between January 1999 and March 2021. Two reviewers independently evaluated the search results and identified studies for inclusion based on the following criteria: participants had a confirmed diagnosis of GHD (as defined in each study); participants were pediatric patients who were receiving GH or had stopped GH treatment, regardless of whether they were pre- or post-pubertal; the intervention was recombinant human GH (rhGH; somatropin); and outcomes included changes in body composition during or after stopping GH therapy. Data extracted from each study included study quality, study sample characteristics, study interventions, and body composition. Data on fat-free mass and LBM were combined into a single category of LBM. Sixteen studies reporting changes in body composition (i.e., FM and LBM) associated with GH treatment in children with GHD were identified and included in the review. Collectively, these studies demonstrated that FM decreased, and LBM increased in response to GH replacement therapy. Despite study limitations (i.e., potential effects of diet and physical activity were not considered), we concluded that a periodic body composition assessment is required to ensure that a satisfactory body composition is achieved during GH replacement therapy in children with GHD.
Sections du résumé
Background
Growth hormone (GH) affects metabolism and regulates growth in childhood. The most prominent feature of GH deficiency (GHD) in children is diminished height velocity that eventually leads to short stature. In adult-onset GHD, lean body mass (LBM) is reduced, and visceral fat mass (FM) increased. Beneficial effects of GH treatment on body composition in adults with GHD, including an increase in muscle mass and a decrease in FM, are well established. Relatively few studies have investigated the effects of GH treatment on the body composition of pediatric patients with idiopathic or hypothalamic-pituitary disease-associated GH deficiency. This systematic review aimed to summarize available evidence relating to the effects of GH treatment on body composition in children with GHD.
Methods
The PubMed, Science Direct, Cochrane Trials, and Embase databases, were searched with keywords including "GH", "body composition", "children", and "growth hormone" for English-language articles, published between January 1999 and March 2021. Two reviewers independently evaluated the search results and identified studies for inclusion based on the following criteria: participants had a confirmed diagnosis of GHD (as defined in each study); participants were pediatric patients who were receiving GH or had stopped GH treatment, regardless of whether they were pre- or post-pubertal; the intervention was recombinant human GH (rhGH; somatropin); and outcomes included changes in body composition during or after stopping GH therapy. Data extracted from each study included study quality, study sample characteristics, study interventions, and body composition. Data on fat-free mass and LBM were combined into a single category of LBM.
Results
Sixteen studies reporting changes in body composition (i.e., FM and LBM) associated with GH treatment in children with GHD were identified and included in the review. Collectively, these studies demonstrated that FM decreased, and LBM increased in response to GH replacement therapy.
Conclusion
Despite study limitations (i.e., potential effects of diet and physical activity were not considered), we concluded that a periodic body composition assessment is required to ensure that a satisfactory body composition is achieved during GH replacement therapy in children with GHD.
Identifiants
pubmed: 36843617
doi: 10.3389/fendo.2023.1093691
pmc: PMC9947344
doi:
Substances chimiques
Growth Hormone
9002-72-6
Human Growth Hormone
12629-01-5
Types de publication
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1093691Informations de copyright
Copyright © 2023 Ferruzzi, Vrech, Pietrobelli, Cavarzere, Zerman, Guzzo, Flodmark, Piacentini and Antoniazzi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Horm Res. 2004;62 Suppl 3:35-41
pubmed: 15539797
J Clin Densitom. 2020 Oct - Dec;23(4):664-672
pubmed: 30992223
Growth Horm IGF Res. 2016 Jun;28:3-5
pubmed: 26936284
Obes Res. 2004 Dec;12(12):1925-9
pubmed: 15687392
Nutrients. 2021 Sep 28;13(10):
pubmed: 34684432
Clin Nutr. 2012 Dec;31(6):854-61
pubmed: 22698802
Nutrition. 2020 Mar;71:110608
pubmed: 31783261
Metabolism. 2001 May;50(5):537-47
pubmed: 11319714
J Clin Endocrinol Metab. 1996 Jul;81(7):2613-20
pubmed: 8675586
Nat Rev Endocrinol. 2021 Oct;17(10):608-624
pubmed: 34417587
Quant Imaging Med Surg. 2020 Aug;10(8):1687-1698
pubmed: 32742961
Am J Clin Nutr. 1993 Jun;57(6):845-50
pubmed: 8503351
Sci Rep. 2017 Jan 10;7:40389
pubmed: 28071718
Arch Osteoporos. 2018 Sep 14;13(1):97
pubmed: 30218261
Clin Endocrinol (Oxf). 2019 Sep;91(3):432-439
pubmed: 31116442
J Clin Epidemiol. 1995 Nov;48(11):1361-7
pubmed: 7490599
Growth Horm IGF Res. 2007 Dec;17(6):463-71
pubmed: 17566776
Clin Endocrinol (Oxf). 2007 Apr;66(4):466-74
pubmed: 17371461
Metabolism. 1973 Apr;22(4):589-95
pubmed: 4696903
J Clin Endocrinol Metab. 1998 Feb;83(2):382-95
pubmed: 9467546
Bone. 2017 Nov;104:101-105
pubmed: 28625918
Endocr Res. 2014;39(2):73-8
pubmed: 24066645
Lipids Health Dis. 2018 Sep 15;17(1):218
pubmed: 30219068
Best Pract Res Clin Endocrinol Metab. 2016 Dec;30(6):757-770
pubmed: 27974189
Ann Lab Med. 2013 Nov;33(6):393-400
pubmed: 24205486
Radiol Med. 2009 Mar;114(2):286-300
pubmed: 19266259
Endocr Regul. 2006 Sep;40(3):69-75
pubmed: 17100548
J Clin Endocrinol Metab. 2001 Oct;86(10):4693-9
pubmed: 11600527
Horm Res. 2002;58(5):207-14
pubmed: 12401939
J Pediatr Endocrinol Metab. 2020 Jul 28;33(7):821-833
pubmed: 32568734
Am J Physiol. 1996 Dec;271(6 Pt 1):E941-51
pubmed: 8997211
Best Pract Res Clin Endocrinol Metab. 2016 Dec;30(6):749-755
pubmed: 27974188
BMJ Paediatr Open. 2020 Apr 29;4(1):e000630
pubmed: 32411831
Indian Pediatr. 2017 Nov 15;54(11):955-960
pubmed: 29217803
J Clin Endocrinol Metab. 2003 Nov;88(11):5101-6
pubmed: 14602733
Clin Endocrinol (Oxf). 2011 Jun;74(6):726-31
pubmed: 21521260
Ann Pediatr Endocrinol Metab. 2017 Sep;22(3):145-152
pubmed: 29025199
Arch Dis Child. 1999 Jun;80(6):517-23
pubmed: 10331999
Endocr Rev. 2005 Feb;26(1):114-46
pubmed: 15689575
PLoS One. 2018 Feb 7;13(2):e0192495
pubmed: 29415060
J Pediatr Endocrinol Metab. 2021 Apr 12;34(6):679-696
pubmed: 33838090
J Clin Endocrinol Metab. 2004 Aug;89(8):3890-5
pubmed: 15292323
J Clin Epidemiol. 2021 Jun;134:178-189
pubmed: 33789819
Contrast Media Mol Imaging. 2019 May 29;2019:3548284
pubmed: 31275083
PLoS One. 2018 Jul 12;13(7):e0200465
pubmed: 30001381
Eur J Endocrinol. 1999 Jan;140(1):35-42
pubmed: 10037249
Bone. 2005 Nov;37(5):642-50
pubmed: 16139578
Clin Endocrinol (Oxf). 2010 Sep;73(3):346-54
pubmed: 20455890
Neuroendocrinology. 2011;93(4):259-64
pubmed: 21454964
Eur J Clin Nutr. 2004 Nov;58(11):1479-84
pubmed: 15138459
Discoveries (Craiova). 2018 Apr 12;6(1):e82
pubmed: 32309600
J Clin Endocrinol Metab. 2000 Oct;85(10):3786-92
pubmed: 11061539
Lancet. 1968 Aug 31;2(7566):492-3
pubmed: 4174509
Nat Rev Endocrinol. 2013 Jun;9(6):346-56
pubmed: 23568441
Endocr J. 1999 Mar;46 Suppl:S35-8
pubmed: 12054115
Curr Opin Clin Nutr Metab Care. 2008 Sep;11(5):566-72
pubmed: 18685451
Am J Clin Nutr. 2016 Mar;103(3):712-6
pubmed: 26843156
Postgrad Med J. 2006 Jan;82(963):24-30
pubmed: 16397076
J Clin Endocrinol Metab. 1999 Dec;84(12):4516-24
pubmed: 10599711